CD19 and B-cell chronic lymphocytic leukemia: determined that remission following CD19-directed CAR T therapy for chronic lymphocytic leukemia was associated with factors such as enrichment in memory-related genes and STAT3 pathway activity at the pre-CAR T treatment baseline (15).